HCV Updates and Insights
Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection.
Collins LF, et al. Open Forum Infect Dis. 2018;5(1):ofx264.
Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease.
Ladino M, et al. World J Hepatol. 2017;9(19):833-839.
Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health.
Morris MD, et al. Int J Prison Health. 2017;13(3-4):192-199.
Retention in buprenorphine treatment is associated with improved HCV care outcomes.
Norton BL, et al. J Subst Abuse Treat. 2017;75:38-42.
The syndemic of opioid misuse, overdose, HCV, and HIV: structural-level causes and interventions.
Perlman DC, Jordan AE. Curr HIV/AIDS Rep. 2018;15(2):96-112.
Primary care for persons who inject drugs.
Visconti AJ, et al. Am Fam Physician. 2019;99(2):109-116.
Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV.
Young J, et al. Clin Infect Dis. 2017;64(9):1154-1162.
Action and Advocacy
EDUCATION AND TRAINING
Health literacy and liver disease.
Gulati R, et al. Clin Liver Dis. 2018;11(2):48-51.
Hepatitis Education Project.
The Hepatitis Education Project provides support, education, advocacy, and direct services for people affected by hepatitis, and works to raise hepatitis awareness among patients, medical providers, and the general public.
National Hepatitis Corrections Network.
The National Hepatitis Corrections Network (NHCN) supports a public health approach to hepatitis education, prevention, testing, and treatment in prisons and jails.
Project ECHO (Extension for Community Healthcare Outcomes).
Project ECHO is a collaborative, telecommunications-based model of medical education and care management designed to train primary care clinicians to provide specialty care in rural and underserved areas.
PUBLIC POLICY: EXPANSION OF ACCESS TO CARE
Drug purchasing strategies to treat people with hepatitis C in the criminal justice system.
Akiyama MJ, et al. Am J Public Health. 2018;108(5):607-608.
Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and National Viral Hepatitis Roundtable (NVHR).
Together, CHLPI and NVHR continue to play a pivotal role in removing Medicaid restrictions on HCV treatment. An interactive map allows you to see each state’s Medicaid restrictions. Last updated November 2018.
Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial.
Kattakuzhy S, et al. Ann Intern Med. 2017;167(5):311-318.
SUPPORT-SERVICES NETWORKING
North American Syringe Exchange Network (NASEN).
NASEN provides a directory of syringe exchange programs that can be located by zip code, landmark, city, or state.
SAMHSA: Behavioral Health Treatment Services Locator.
SAMHSA provides confidential and anonymous information on substance abuse and mental health treatment facilities throughout the United States and its territories.
SAMHSA: Medication-Assisted Treatment (MAT) Support Organizations.
SAMHSA provides numerous links to nonprofit associations, federal agencies, and patient groups that offer support for providers of medication-assisted treatment (MAT), as well as their patients and families.
Patient Resources
Hepatitis C Information Center
American Liver Foundation, 2018.
The American Liver Foundation’s Hepatitis C Information Center website is a dedicated online information and resource center created in support of individuals impacted by HCV infection.
Project Inform
Project Inform provides up-to-date information to help people living with HIV and HCV make the best choices regarding their treatment and care.
Appendix
Complete List of References Associated With Figure Titled Real-World Evidence.
Conway B, et al. American Association for the Study of Liver Diseases. The Liver Meeting® 2016 – AASLD. November 11−15, 2016; Boston, MA. Poster 1992.
Dore GJ, et al. Ann Intern Med. 2016;165(9):625-634.
Drugs@FDA. 2018. https://www.accessdata.fda.gov/scripts/cder/daf/.
Grebely J, et al. Clin Infect Dis. 2016;63(11):1405-1411.
Grebely J, et al. Clin Infect Dis. 2016;63(11):1479-1481.
Grebely J, et al. J Hepatol. 2017;66:S513-S514.
Kiser JJ. Top Antivir Med. 2016;24(3):106-110.
Naggie SD, et al. N Engl J Med. 2015;373(8):705-713.
Osinusi A, et al. JAMA. 2015;313(12):1232-1239.
Puoti M, et al. J Hepatol. 2018;69(2):293-300.
Rockstroh JK, et al. Clin Infect Dis. 2018;67(7):1010-1017.
Rockstroh JK, et al. Lancet HIV. 2015;2(8):e319-e327.
Rockstroh JK. European Association for the Study of the Liver. The International Liver Congress™ − EASL 2017. April 19-23, 2017; Amsterdam, The Netherlands.
Sulkowski MS, et al. JAMA. 2015;313(12):1223-1231.
Wyles D, et al. Clin Infect Dis. 2017;65(1):6-12.
Zeuzem S, et al. Ann Intern Med. 2015;163(1):1-13.
Clinical Practice Guidelines
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV.
US Department of Health and Human Services, 2017 (last updated October 2018).
Evaluation and Management of Chronic Hepatitis C Virus (HCV) Infection.
Federal Bureau of Prisons Clinical Guidance. 2018.
HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.
American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA), 2017.
Clinical Resources
Harm Reduction Coalition.
HEP Drug Interactions.
University of Liverpool, 2019.
Opioid Overdose Prevention Toolkit.
Substance Abuse and Mental Health Services Administration (SAMHSA).
HCV Updates and Insights
Realities, Challenges, and Opportunities to Improve Care
| Faculty: | Matthew Akiyama, MD, MSc; Mandy Altman, MPA, CCHP; Lara Strick, MD, MSc; Tracy Swan; Alysse G. Wurcel, MD, MS |
| Release: | 05/08/2019 |
| Expiration: | 05/08/2020 |
